Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology
10 févr. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 10, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a...
iBio Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline
30 janv. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 30, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biopharmaceutical products, has added a...
iBio Receives Allowance of Patent for HPV-Related Cancer Vaccine in China
21 janv. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 21, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has received a notice...
iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
15 janv. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 15, 2014) - iBio, Inc. (NYSE MKT: IBIO) announced today that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer...